MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar btthus (50.22) Submitted: 2/1/2011 11:00:29 PM : Outperform Start Price: $4.75 MNKD Score: -65.30

$5 M in insider buying

Featured Broker Partners


Advertisement